ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO080

Depletion of Gprc5a Promotes Development of Diabetic Nephropathy

Session Information

Category: Glomerular

  • 1002 Glomerular: Basic/Experimental Pathology

Authors

  • Patrakka, Jaakko, Karolinska Institutet, Huddinge, Sweden
  • Lal, Mark, AstraZeneca, Gothenburg, Sweden
  • Zambrano Sevilla, Sonia, None, Seville, AND, Spain
Background

Renal glomeruli are the primary target of injury in diabetic nephropathy (DN). In the glomerulus, damage to podocyte cells plays a critical role in the disease progression. Transforming growth factor beta (TGF-β) signaling is involved in the pathogenesis but mechanisms regulating this pathway in podocytes are poorly understood. G-protein coupled receptors (GPCRs) have been the most successful protein class for drug discovery as 20-40% of currently clinically approved drugs are targeting them. In this study, we investigated glomerular GPCRs in DN with the aim of identifying novel molecular targets for pharmaceutical intervention.

Results

We performed high throughput molecular profiling of GPCRs in human glomeruli and identified an orphan GPCR, Gprc5a, as a novel highly podocyte-specific molecule whose expression was significantly down-regulated in patients with DN. Inactivation of Gprc5a in mouse resulted in thickening of the glomerular basement membrane and activation of mesangial cells, which are two hallmark features of DN in humans. Gprc5a-deficient animals were susceptible to diabetic glomerular damage as demonstrated by higher albuminuria and more severe histological changes after induction of diabetes with streptozotocin. Mechanistically, we show that Gprc5a modulates TGF-β signaling pathway in podocytes through activation of epidermal growth factor receptor (EGFR).

Conclusion

We conclude that depletion of Gprc5a promotes the progression of DN. Gprc5a can provide us a possibility to develop pharmaceutical tools to manipulate pathogenic signaling pathways in a podocyte-specific manner.

Funding

  • Commercial Support